Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Literature
1.
Liu MT, Hsieh CY, Wang AY, Chang TH, Pi CP, Huang CC, Huang CY, Liou CH (2006) Prognostic factors affecting the outcome of brain metastases from breast cancer. Support Care Cancer 14:936–942PubMedCrossRef
2.
Altundag K, Bondy ML, Kau SW, Broglio K, Rivera E (2005) Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastases. Breast Cancer Res Treat 94 (Suppl 1):S143(Abstract 3056)
Metadata
Title
Hormone receptor status as a prognostic factor affecting the outcome of brain metastases
Authors
Hakan Harputluoglu
Tugrul Purnak
Kadri Altundag
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 3/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0157-z

Other articles of this Issue 3/2007

Supportive Care in Cancer 3/2007 Go to the issue

Original Article

Interaction of psychological factors and the effect of epoetin alfa treatment in cancer patients on hemoglobin and fatigue

Original Article

The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone

Review Article

Levorphanol: the forgotten opioid

Forthcoming Meetings

Forthcoming Meetings

Original Article

Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial

Original Article

How important is the opinion of significant others to cancer patients’ adjuvant chemotherapy decision-making?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits